Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Stifel raised its price target on Soleno Therapeutics Inc. (NASDAQ:SLNO) to $115.00 from $108.00 on Monday, while maintaining a Buy rating on the stock. The company, currently valued at $4.28 billion, has seen its stock surge over 111% in the past year, according to InvestingPro data.
The price target increase follows a survey of 20 physicians that Stifel conducted, which showed significant demand for Soleno’s drug Vykat, with 70% of doctors prescribing the medication—most to multiple patients.
The survey revealed unexpected adult utilization consistent with pediatric use, which Stifel noted could be a significant tailwind for the company. Physicians reported favorable views of Vykat’s clinical profile regarding efficacy, safety, and monitoring requirements.
Early reimbursement dynamics for the drug appear better than anticipated, with most physicians able to get the majority of prescriptions approved, according to the survey results.
Stifel now models approximately $2.5 billion in peak sales for Vykat, with physicians expecting utilization to increase meaningfully throughout 2025 and sustained growth in 2026 with greater than 50% market penetration.
In other recent news, Soleno Therapeutics has reported promising developments surrounding its VYKAT XR treatment for Prader-Willi syndrome (PWS). Piper Sandler reiterated an Overweight rating with a $145.00 price target, highlighting strong early adoption of VYKAT XR, which is expected to exceed market expectations. Wall Street projections estimate VYKAT XR sales to reach $3.9 million in the second quarter of 2025 and $409.1 million for the full year. Piper Sandler, however, anticipates sales could surpass $2 billion, given the addressable U.S. PWS population and early interest from prescribers.
Additionally, new data presented at the United in Hope conference showed that VYKAT XR significantly reduces hyperphagia symptoms in patients with strict food controls, and it is safe for those with pre-diabetes or diabetes. TD Cowen initiated coverage with a Buy rating and a $110.00 price target, citing the drug’s approval as a major milestone in treating PWS. Stifel analysts also maintained a Buy rating with a $108.00 target, noting encouraging initial launch dynamics and positive interactions with payors.
Soleno is preparing for a European launch, with a Marketing Authorization Application filed for VYKAT XR, and potential approval anticipated by early 2026. The company’s management team remains optimistic about VYKAT XR’s competitive position and patent portfolio, which could strengthen its market standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.